Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings
Integrating IRIS technologies will allow Topcon to improve retinal disease diagnostics and referrals from primary care providers.
S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
The DRD Cure Accelerator, highlighted at the CCOI-Stanford Summit, is a global initiative advancing clinical research and collaborations to eliminate vision loss from diabetic retinal disease.
Retinal microvasculature on OCTA may predict coronary artery disease risk
Japanese researchers link outdoor time to rapid increase in choroidal thickness
Phase 3 study of LUMIFY Preservative Free and LUMIFY eye drops meets primary end point
What to expect from ASRS 2025
In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Ophthalmology spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.
Alcon to showcase next-gen retina tools and clinical data at ASRS annual meeting
Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System
Bascom Palmer Eye Institute ranked as top ophthalmology hospital in US for 22nd year in a row
The annual Best Hospitals report from US News & World Report compares more than 4,500 hospitals across 15 specialties and 22 procedures and conditions.
Alteogen receives positive CHMP opinion for aflibercept biosimilar, EYLUXVI
Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies
CORXEL submits NDA for LNZ100 in China for presbyopia treatment
LENZ Therapeutics previously licensed Greater China rights to CORXEL for the development and commercialization of LNZ100 in April 2022.
Alkeus Pharmaceuticals to present TEASE and SAGA study data at ASRS 2025
Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long Beach, California.
Part 7: Looking back at 50 years of innovation in ophthalmology
To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA
Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa
Most Americans avoid eye exams due to perceived non-urgency, confusion about benefits
A recent study reveals that many Americans neglect eye care due to cost and urgency misconceptions, despite the significant impact on daily life.
Part 6: Looking back at 50 years of innovation in ophthalmology
NEW DAY trial of ILUVIEN for DME does not meet primary endpoint, post-hoc analysis suggests potential benefits
Q&A: Natalie Afshari, MD, FACS, championing on-label pediatric IOLs: turning advocacy into access
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy
Vonaprument has received fast track designation from the US Food and Drug Administration.
Kiora Pharmaceuticals Secures US Patent for KIO-104
KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular degeneration (AMD), and complications as a result of refractive surgery.
Scuba divers and surfers face dual light exposure that may accelerate AMD
Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.
Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence
At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.
Part 5: Looking back at 50 years of innovation in ophthalmology
First US patient receives Eyetronic glaucoma treatment at Glaucoma Center of San Francisco
Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.
Researchers explore ChatGPT4o's ability to generate realistic retinal fundus images
OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.
Role of mucormycosis infection on vision in diabetic patient
CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.
Ocugen announces appointments to retina scientific advisory board and executive leadership team
These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.
Part 4: Looking back at 50 years of innovation in ophthalmology
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.
